1134 related articles for article (PubMed ID: 24321621)
1. Experimental Chagas disease. Innate immune response in Balb/c mice previously vaccinated with Trypanosoma rangeli. I. The macrophage shows immunological memory: Reality or fiction?
Basso B; Marini V
Immunobiology; 2014 Apr; 219(4):275-84. PubMed ID: 24321621
[TBL] [Abstract][Full Text] [Related]
2. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction?
Basso B; Marini V
Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810
[TBL] [Abstract][Full Text] [Related]
3. Acute Trypanosoma cruzi infection: IL-12, IL-18, TNF, sTNFR and NO in T. rangeli-vaccinated mice.
Basso B; Cervetta L; Moretti E; Carlier Y; Truyens C
Vaccine; 2004 May; 22(15-16):1868-72. PubMed ID: 15121297
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with Trypanosoma rangeli induces resistance of guinea pigs to virulent Trypanosoma cruzi.
Basso B; Moretti E; Fretes R
Vet Immunol Immunopathol; 2014 Jan; 157(1-2):119-23. PubMed ID: 24275040
[TBL] [Abstract][Full Text] [Related]
5. Can we heal Chagas infection?
Vega Royero SP; Sibona GJ
J Theor Biol; 2014 Jan; 340():23-9. PubMed ID: 24029157
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with Trypanosoma rangeli modulates the profiles of immunoglobulins and IL-6 at local and systemic levels in the early phase of Trypanosoma cruzi experimental infection.
Marini V; Moretti E; Bermejo D; Basso B
Mem Inst Oswaldo Cruz; 2011 Feb; 106(1):32-7. PubMed ID: 21340352
[TBL] [Abstract][Full Text] [Related]
7. Comparative Analysis of the Secretome and Interactome of
Watanabe Costa R; Batista MF; Meneghelli I; Vidal RO; Nájera CA; Mendes AC; Andrade-Lima IA; da Silveira JF; Lopes LR; Ferreira LRP; Antoneli F; Bahia D
Front Immunol; 2020; 11():1774. PubMed ID: 32973747
[TBL] [Abstract][Full Text] [Related]
8. Trypanosoma cruzi: protective response of vaccinated mice is mediated by CD8+ cells, prevents signs of polyclonal T lymphocyte activation, and allows restoration of a resting immune state after challenge.
Paiva CN; Castelo-Branco MT; Lannes-Vieira J; Gattass CR
Exp Parasitol; 1999 Jan; 91(1):7-19. PubMed ID: 9920038
[TBL] [Abstract][Full Text] [Related]
9. Immune response and Trypanosoma cruzi infection in Trypanosoma rangeli-immunized mice.
Basso B; Moretti ER; Vottero-Cima E
Am J Trop Med Hyg; 1991 Apr; 44(4):413-9. PubMed ID: 1828328
[TBL] [Abstract][Full Text] [Related]
10.
Gupta S; Salgado-Jiménez B; Lokugamage N; Vázquez-Chagoyán JC; Garg NJ
Front Immunol; 2019; 10():1456. PubMed ID: 31293599
[No Abstract] [Full Text] [Related]
11. Vaccination with epimastigotes of different strains of Trypanosoma rangeli protects mice against Trypanosoma cruzi infection.
Basso B; Moretti E; Fretes R
Mem Inst Oswaldo Cruz; 2008 Jun; 103(4):370-4. PubMed ID: 18660992
[TBL] [Abstract][Full Text] [Related]
12. Trypanosoma rangeli: epimastigote immunogenicity and cross-reaction with Trypanosoma cruzi.
Saldaña A; Sousa OE
J Parasitol; 1996 Apr; 82(2):363-6. PubMed ID: 8604121
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of dogs with Trypanosoma rangeli induces antibodies against Trypanosoma cruzi in a rural area of Córdoba, Argentina.
Basso B; Marini V; Gauna D; Frias M
Mem Inst Oswaldo Cruz; 2016 Apr; 111(4):271-4. PubMed ID: 27074257
[TBL] [Abstract][Full Text] [Related]
14. Protective effect of Trypanosoma rangeli against infections with a highly virulent strain of Trypanosoma cruzi.
Zuñiga C; Palau T; Penin P; Gamallo C; de Diego JA
Trop Med Int Health; 1997 May; 2(5):482-7. PubMed ID: 9217704
[TBL] [Abstract][Full Text] [Related]
15. [Immune response to Trypanosoma cruzi. An approach to the pathogenesis of Chagas' disease].
Braun M; de Titto E
Acta Physiol Pharmacol Latinoam; 1985; 35(1):1-47. PubMed ID: 2932884
[TBL] [Abstract][Full Text] [Related]
16. Action of Trypanosoma rangeli in infections with virulent Trypanosoma cruzi populations.
Paláu MT; Mejía AJ; Vergara U; Zúñiga CA
Mem Inst Oswaldo Cruz; 2003 Jun; 98(4):543-8. PubMed ID: 12937771
[TBL] [Abstract][Full Text] [Related]
17. Trypanosoma cruzi-infected macrophages are defective in major histocompatibility complex class II antigen presentation.
La Flamme AC; Kahn SJ; Rudensky AY; Van Voorhis WC
Eur J Immunol; 1997 Dec; 27(12):3085-94. PubMed ID: 9464791
[TBL] [Abstract][Full Text] [Related]
18. [Experimental Chagas' disease: I. Study of different immunization conditions in the infection course].
Introini MV; Basso B; Moretti E
Bol Chil Parasitol; 1998; 53(3-4):45-51. PubMed ID: 10413878
[TBL] [Abstract][Full Text] [Related]
19. TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice.
Hegazy-Hassan W; Zepeda-Escobar JA; Ochoa-García L; Contreras-Ortíz JME; Tenorio-Borroto E; Barbabosa-Pliego A; Aparicio-Burgos JE; Oros-Pantoja R; Rivas-Santiago B; Díaz-Albiter H; Garg NJ; Vázquez-Chagoyán JC
Vaccine; 2019 Jan; 37(2):248-257. PubMed ID: 30497833
[TBL] [Abstract][Full Text] [Related]
20. MIF-driven activation of macrophages induces killing of intracellular Trypanosoma cruzi dependent on endogenous production of tumor necrosis factor, nitric oxide and reactive oxygen species.
Cutrullis RA; Petray PB; Corral RS
Immunobiology; 2017 Feb; 222(2):423-431. PubMed ID: 27591076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
